

BioCardia, Inc.
Selected Balance Sheet Data
(amounts in thousands)

	<u>June 30,</u> <u>2023⁽¹⁾</u>	<u>December 31,</u> <u>2022⁽¹⁾</u>
Assets:		
Cash and cash equivalents	\$ 4,305	\$ 7,363
Other current assets	345	501
Property, equipment and other noncurrent assets	<u>1,739</u>	<u>1,929</u>
Total assets	<u>\$ 6,389</u>	<u>\$ 9,793</u>
Liabilities and Stockholders' Equity		
Current liabilities	\$ 3,616	\$ 3,585
Operating lease liability - noncurrent	1,138	1,316
Total stockholders' equity	<u>1,635</u>	<u>4,892</u>
Total liabilities and stockholders' equity	<u>\$ 6,389</u>	<u>\$ 9,793</u>

(1) June 30, 2023 amounts are unaudited. December 31, 2022 amounts were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission on March 29, 2023.

BIOCARDIA, INC.
Condensed Statements of Operations
(Unaudited In thousands, except share and per share amount)

	Three Months ended		Six Months ended	
	June 30,		June 30,	
	2023	2022	2023	2022
Revenue:				
Net product revenue	\$ —	\$ —	\$ —	\$ 1
Collaboration agreement revenue	43	974	107	1,033
Total revenue	43	974	107	1,034
Costs and expenses:				
Research and development	2,314	2,304	4,698	4,490
Selling, general and administrative	1,181	1,166	2,371	2,367
Total costs and expenses	3,495	3,470	7,069	6,857
Operating loss	(3,452)	(2,496)	(6,962)	(5,823)
Other income (expense):				
Total other income (expense), net	28	(1)	37	1
Net loss	\$ (3,424)	\$ (2,497)	\$ (6,925)	\$ (5,822)
Net loss per share, basic and diluted	\$ (0.17)	\$ (0.14)	\$ (0.34)	\$ (0.34)
Weighted-average shares used in computing net loss per share, basic and diluted	20,384,522	17,651,892	20,281,417	17,360,598